Document:

Exhibit 4.1

 

THIS
NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”)

 

US
$131,250.00

 

ADHERA
THERAPEUTICS, INC.

10%
CONVERTIBLE REDEEMABLE NOTE

DUE
OCTOBER 7, 2022

 

FOR
VALUE RECEIVED, ADHERA THERAPEUTICS, INC. (the “Company”) promises to pay to the order of BLUE LAKE PARTNERS, LLC and its
authorized successors and Permitted Assigns, defined below, (“Holder”), the aggregate principal face amount One Hundred
Thirty One Thousand Two Hundred Fifty Dollars exactly (U.S. $131,250.00) on October 7, 2022 (“Maturity Date”) and
to pay interest on the principal amount outstanding hereunder at the rate of 10% per annum commencing on October 7, 2021 (“Issuance
Date”). The Company acknowledges this Note was issued with a $6,250.00 original issue discount and as such the purchase price
was $125,000.00. The interest will be paid to the Holder in whose name this Note is registered on the records of the Company regarding
registration and transfers of this Note. The principal of, and interest on, this Note are payable at 3411 Silverside Road, Tatnal Building
#104, Wilmington, DE 19810, initially, and if changed, last appearing on the records of the Company as designated in writing by the Holder
hereof from time to time. The Company will pay each interest payment and the outstanding principal due upon this Note before or on the
Maturity Date, less any amounts required by law to be deducted or withheld, to the Holder of this Note by check or wire transfer addressed
to such Holder at the last address appearing on the records of the Company. The forwarding of such check or wire transfer shall constitute
a payment of outstanding principal hereunder and shall satisfy and discharge the liability for principal on this Note to the extent of
the sum represented by such check or wire transfer. Interest shall be payable in Common Stock (as defined below) pursuant to paragraph
4(b) herein. Permitted Assigns means any Holder assignment, transfer or sale of all or a portion of this Note accompanied by an opinion
of counsel as provided for in Section 2(f) of the securities purchase agreement entered into between the Company and the Holder with
respect to this Note (the “Securities Purchase Agreement”).

 

     

     

    

 

This
Note is subject to the following additional provisions:

 

1. This
Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the Holder
surrendering the same. No service charge will be made for such registration or transfer or exchange, except that Holder shall pay any
tax or other governmental charges payable in connection therewith. To the extent that Holder subsequently transfers, assigns, sells or
exchanges any of the multiple lesser denomination notes, Holder acknowledges that it will provide the Company with opinions of counsel
as provided for in Section 2(f) of the Securities Purchase Agreement.

 

2. The
Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

 

3. This
Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended (“Act”) and applicable
state securities laws. Any attempted transfer to a non-qualifying party shall be treated by the Company as void. Prior to due presentment
for transfer of this Note, the Company and any agent of the Company may treat the person in whose name this Note is duly registered on
the Company’s records as the owner hereof for all other purposes, whether or not this Note be overdue, and neither the Company
nor any such agent shall be affected or bound by notice to the contrary. Any Holder of this Note electing to exercise the right of conversion
set forth in Section 4(a) hereof, in addition to the requirements set forth in Section 4(a), and any prequalified prospective transferee
of this Note, also is required to give the Company written confirmation that this Note is being converted (“Notice of Conversion”)
in the form annexed hereto as Exhibit A. The date of receipt (including receipt by telecopy) of such Notice of Conversion shall
be the Conversion Date.

 

    2

     

    

 

4. (a) The Holder of this Note is entitled, at its option, at any time after cash payment, to convert all or any amount of the
principal face amount of this Note then outstanding into shares of the Company’s common stock (the “Common
Stock”) at a price for each share of Common Stock equal to $0.075 per share (“Conversion Price”).
The Conversion Price is subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower
relating to the Borrower’s securities or the securities of any subsidiary of the Borrower, combinations, recapitalization,
reclassifications, extraordinary distributions and similar events. If the shares have not been delivered within 3 business days, the
Notice of Conversion may be rescinded in addition to all other rights and remedies that Holder may be entitled to. Such conversion
shall be effectuated by the Company delivering the shares of Common Stock to the Holder within 3 business days of receipt by the
Company of the Notice of Conversion. Accrued but unpaid interest shall be subject to conversion. No fractional shares or scrip
representing fractions of shares will be issued on conversion, but the number of shares issuable shall be rounded to the nearest
whole share. To the extent the Conversion Price of the Company’s Common Stock closes below the par value per share, the
Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value
possible under law. The Company agrees to honor all conversions submitted pending this increase. In no event shall the Holder be
allowed to effect a conversion if such conversion, along with all other shares of Company Common Stock beneficially owned by the
Holder and its affiliates would exceed 4.99% of the outstanding shares of the Common Stock of the Company (which may be increased up
to 9.9% upon 60 days’ prior written notice by the Investor). If the Company, at any time while this Note or any amounts due
hereunder are outstanding, issues, sells or grants (or has issued, sold or granted as of the Issuance Date, as the case may be) any
option to purchase, or sells or grants any right to reprice, or otherwise disposes of, or issues (or has sold or issued, as the case
may be, or announces any sale, grant or any option to purchase or other disposition), any Common Stock or other securities
convertible into, exercisable for, or otherwise entitle any person or entity the right to acquire, shares of Common Stock
(including, without limitation, upon conversion of this Note, and any convertible notes or warrants outstanding as of or following
the Issuance Date), in each or any case at an effective price per share that is lower than the then Conversion Price (such lower
price, the “Base Conversion Price” and such issuances, collectively, a “Dilutive Issuance”) (it being agreed
that if the holder of the Common Stock or other securities so issued shall at any time, whether by operation of purchase price
adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights
per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per
share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on
such date of the Dilutive Issuance), then the Conversion Price shall be reduced, at the option of the Holder, to a price equal to
the Base Conversion Price. Such adjustment shall be made whenever such Common Stock or other securities are issued. By way of
example, and for the avoidance of doubt, if the Company issues a convertible promissory note, and the holder of such convertible
promissory note has the right to convert it into Common Stock at an effective price per share that is lower than the then Conversion
Price, then the Holder has the right to reduce the Conversion Price to such Base Conversion Price in perpetuity regardless of
whether the holder of such convertible promissory note ever effectuated a conversion at the Base Conversion Price. Notwithstanding
the foregoing, no adjustment shall be made under this Section 4(a) in respect of any Exempt Issuance (as defined in this Note).
“Exempt Issuance” means the issuance of (a) shares of Common Stock, restricted stock units or options to consultants,
employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of
the members of the Board of Directors or a majority of the members of a committee of directors established for such purpose for
services rendered to the Company, (b) securities issued upon the exercise or exchange of or conversion of any securities issued
under the Securities Purchase Agreement between the Holder and the Company dated as of the dated of this Note, (c) securities issued
pursuant to any merger, acquisition or strategic transaction approved by a majority of the directors of the Company, provided
that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its
subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and which
shall reasonably be expected to provide to the Company additional benefits, but shall not include a transaction in which the Company
is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
securities, (d) securities issued pursuant to any purchase money equipment loan or capital leasing arrangement or debt financing
from a commercial bank or similar financial institution, or (e) securities issued to any placement agent or underwriter as
compensation for services. The word Person means an individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or
other entity of any kind.

 

    3

     

    

 

(b) Interest
on any unpaid principal balance of this Note shall be paid at the rate of 10% per annum. Interest may be paid by the Company in Common
Stock (“Interest Shares”) if the Holder elects to convert such interest into Common Stock. Holder may, at any time, send
in a Notice of Conversion to the Company for Interest Shares based on the formula provided in Section 4(a) above. The dollar amount converted
into Interest Shares shall be all or a portion of the accrued interest calculated on the unpaid principal balance of this Note to the
date of such notice.

 

(c)
The Notes may be prepaid or assigned with the following penalties/premiums:

 

	PREPAY
    DATE	 	PREPAY
    AMOUNT
	1-180
    calendar days after the Issuance Date	 	100%
    of principal plus accrued interest

 

This
Note may not be prepaid after the 180th calendar day. Such redemption must be closed and funded within 3 days of giving notice
of redemption or the right to redeem shall be null and void. Any partial prepayments will be made in accordance with the formula set
forth in the chart above with respect to principal and interest.

 

(d) Upon (i) a transfer of all or substantially all of the assets of the Company to any person
in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization (excluding an increase in
authorized capital) or other change or exchange of outstanding shares of the Common Stock, other than a forward or reverse stock split
or stock dividend, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is
not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and
results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) (each
of items (i), (ii) and (iii) being referred to as a “Sale Event”), then, in each case, the Company shall, upon request of
the Holder, redeem this Note in cash for 150% of the principal amount, plus accrued but unpaid interest through the date of redemption,
or at the election of the Holder, such Holder may convert the unpaid principal amount of this Note (together with the amount of accrued
but unpaid interest) into shares of Common Stock immediately prior to such Sale Event at the Conversion Price.

 

    4

     

    

 

(e)  In case of any Sale Event (not to include a sale of all or substantially all of the Company’s
assets) in connection with which this Note is not redeemed or converted, the Company shall cause effective provision to be made so that
the Holder of this Note shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and
number of shares of stock or other securities or property (including cash) receivable upon such reclassification, capital reorganization
or other change, consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise
of the Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The foregoing provisions
shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash, the
value shall be as determined by the Board of Directors of the Company or successor person or entity acting in good faith.

 

5. No
provision of this Note shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal
of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

 

6. The
Company hereby expressly waives demand and presentment for payment, notice of non-payment, protest, notice of protest, notice of dishonor,
notice of acceleration or intent to accelerate, and diligence in taking any action to collect amounts called for hereunder and shall
be directly and primarily liable for the payment of all sums owing and to be owing hereto.

 

7. The
Company agrees to pay all costs and expenses, including reasonable attorneys’ fees and expenses, which may be incurred by the Holder
in collecting any amount due under this Note.

 

8. If
one or more of the following described “Events of Default” shall occur:

 

(a) The
Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company; or

 

(b) Any
of the representations or warranties made by the Company herein or in any agreement entered into by the Company in connection with the
execution and delivery of this Note, shall be false or misleading in any respect; or

 

(c) The
Company shall fail to perform or observe, in any respect, any covenant, term, provision, condition, agreement or obligation of the Company
under this Note, the Securities Purchase Agreement, the Warrant (as defined in the Securities Purchase Agreement) (the “Warrant”),
any other note issued to the Holder, or any other documentation entered into between the Company and the Holder with respect to the aforementioned
items; or

 

(d) The
Company shall (1) become insolvent (which does not include a “going concern opinion); (2) admit in writing its inability to pay
its debts generally as they mature; (3) make an assignment for the benefit of creditors or commence proceedings for its dissolution;
(4) apply for or consent to the appointment of a trustee, liquidator or receiver for its or for a substantial part of its property or
business; (5) file a petition for bankruptcy relief, consent to the filing of such petition or have filed against it an involuntary petition
for bankruptcy relief, all under federal or state laws as applicable, which involuntary petition has not been vacated within 60 days
of filing; or

 

    5

     

    

 

(e) A
trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without its
consent and shall not be discharged within sixty (60) days after such appointment; or

 

(f) Any
governmental agency or any court of competent jurisdiction at the instance of any governmental agency shall assume custody or control
of the whole or any substantial portion of the properties or assets of the Company; or

 

(g) One
or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars ($50,000) in the aggregate,
shall be entered or filed against the Company or any of its properties or other assets and shall remain unpaid, unvacated, unbonded or
unstayed for a period of fifteen (15) days or in any event later than five (5) days prior to the date of any proposed sale thereunder;
or

 

(h) Reserved

 

(i) The
Company shall have its Common Stock delisted from an exchange or marketplace (including the OTC Markets marketplace) or, if the Common
Stock trades on an exchange or marketplace, then trading in the Common Stock shall be suspended for more than 10 consecutive days;

 

(j) Reserved

 

(k) The
Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within 3 business
days of its receipt of a Notice of Conversion which includes an opinion of counsel expressing an opinion which supports the removal of
a restrictive legend, provided that the opinion complies with all applicable laws and rules; or

 

(l)  The Company shall not replenish the reserve set forth in Section 12, within 3 business days
of the request of the Holder.

 

(m) [Reserved]

 

(n)  The Company shall cause to lose the “bid” price for its stock in a market (including
the OTC marketplace or other exchange).

 

(o) If,
at any time after the Issuance Date, the Company shall fail to comply in any material respect with the reporting requirements of the
1934 Act (including but not limited to becoming delinquent in its periodic report filings with the Securities and Exchange Commission),
including applicable available extensions, and/or the Company shall cease to be subject to the reporting requirements of the 1934 Act.

 

    6

     

    

 

(p) In
the event that the Company proposes to replace its transfer agent, the Company fails to provide, prior to the effective date of such
replacement, a fully executed irrevocable transfer agent instructions in a form as initially delivered to Holder with respect to this
Note (including but not limited to the provision to irrevocably reserve shares of Common Stock to satisfy the Company’s obligations
under the Note and Warrant) signed by the successor transfer agent and the Company.

 

Then,
or at any time thereafter, and in each and every such case, unless such Event of Default shall have been waived in writing by the Holder
(which waiver shall not be deemed to be a waiver of any subsequent default) at the option of the Holder and in the Holder’s sole
discretion, the Holder may consider this Note immediately due and payable, without presentment, demand, protest or (further) notice of
any kind (other than notice of acceleration), all of which are hereby expressly waived, anything herein or in any note or other instruments
contained to the contrary notwithstanding, and the Holder may immediately, and without expiration of any period of grace, enforce any
and all of the Holder’s rights and remedies provided herein or any other rights or remedies afforded by law. Upon an Event of Default,
interest shall accrue at a default interest rate of 16% per annum or, if such rate is usurious or not permitted by current law, then
at the highest rate of interest permitted by law. In the event of a breach of Section 8(k) the penalty shall be $250 per day the shares
are not issued beginning on the 4th day after the conversion notice was delivered to the Company. This penalty shall increase
to $500 per day beginning on the 10th day. The penalty for a breach of Section 8(n) shall be an increase of the outstanding
principal amount of the Note by 20%.

 

If
the Holder shall commence an action or proceeding to enforce any provisions of this Note, including, without limitation, engaging an
attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Company for its attorneys’ fees and
other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

 

The
Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day from the
time of the Holder’s written notice to the Company.

 

9. In
case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable,
such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity
and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.

 

10. Neither
this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the Company
and the Holder.

 

    7

     

    

 

11. The
Company represents that it is not a “shell” issuer and has never been a “shell” issuer or that if it previously
has been a “shell” issuer that at least 12 months have passed since the Company has reported Form 10 type information indicating
it is no longer a “shell” issuer. Further. The Company will instruct its counsel to either (i) write a 144 opinion to allow
for salability of the conversion shares or (ii) accept such opinion from Holder’s counsel, subject to compliance with applicable
laws and rules.

 

12. The
Company shall issue irrevocable transfer agent instructions reserving 8,552,976 shares of its Common Stock for conversions under this
Note and exercises under the Warrant (the “Share Reserve”). Upon full conversion of this Note and full exercise of the Warrant,
any shares remaining in the Share Reserve shall be cancelled. The Company shall pay all transfer agent costs and legal fees associated
with issuing and delivering the shares to the Holder. If such amounts are to be paid by the Holder, it may deduct such amounts from the
amounts being converted. The Company should at all times reserve a minimum of four times the amount of shares required if the note would
be fully converted. The Holder may reasonably request increases from time to time to reserve such amounts. The Company will instruct
its transfer agent to provide the outstanding share information to the Holder in connection with its conversions.

 

13. The
Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits, recapitalizations
etc. This notice shall be given to the Holder as soon as possible under law.

 

14. If
it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable
provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest permitted under applicable
law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim or take advantage of any law that
would prohibit or forgive the Company from paying all or a portion of the principal or interest on this Note.

 

15. This
Note shall be governed by and construed in accordance with the laws of Delaware and shall be binding upon the successors and assigns
of each party hereto. The Holder and the Company hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue
in the state courts located in Palm Beach County, Florida or in the federal courts located in Palm Beach County, Florida. This Agreement
may be executed in counterparts, and the facsimile transmission of an executed counterpart to this Agreement shall be effective as an
original.

 

16. So
long as this Note is outstanding, upon any issuance by the Company or any of its subsidiaries of any security, or amendment to a security
that was originally issued before the Issuance Date, with any term that the Holder reasonably believes is more favorable to the holder
of such security or with a term in favor of the holder of such security that the Holder reasonably believes was not similarly provided
to the Holder in this Note, then (i) the Company shall notify the Holder of such additional or more favorable term within one (1) business
day of the issuance and/or amendment (as applicable) of the respective security, and (ii) such term, at Holder’s option, shall
become a part of the transaction documents with the Holder (regardless of whether the Company complied with the notification provision
of this Section 16). The types of terms contained in another security that may be more favorable to the holder of such security include,
but are not limited to, conversion price, terms addressing prepayment rate, interest rates, and original issue discounts.

 

    8

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed by an officer thereunto duly authorized.

 

Dated:
October 7, 2021

 

	 	ADHERA THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	Andrew Kucharchuk
	 	Title:	Chief Executive Officer

 

    9

     

    

 

EXHIBIT
A

 

NOTICE
OF CONVERSION

 

(To
be Executed by the Registered Holder in order to Convert the Note)

 

The
undersigned hereby irrevocably elects to convert $___________ of the above Note into _________ Shares of Common Stock of ADHERA THERAPEUTICS,
INC. (“Shares”) according to the conditions set forth in such Note, as of the date written below.

 

If
Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer and other taxes and
charges payable with respect thereto.

 

Date
of Conversion: ________________________________________________________________________________ 

Applicable
Conversion Price: _________________________________________________________________________ 

Signature:
_______________________________________________________________________________________ 

[Print
Name of Holder and Title of Signer]

Address:
________________________________________________________________________________________ 

 _______________________________________________________________________________________

 

SSN
or EIN: ____________________________  

 

Shares
are to be registered in the following name:  _________________________________________________________

 

Name:
__________________________________________________________________________________________  

Address:
 _______________________________________________________________________________________

Tel:
  ________________________________________

Fax:
  ________________________________________

SSN
or EIN:  __________________________________

 

Shares
are to be sent or delivered to the following account:

 

Account
Name: ____________________________________________________________________________  

Address:
 _________________________________________________________________________________

 

    10Exhibit
4.2

 

THIS
WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT OR APPLICABLE EXEMPTION OR SAFE HARBOR PROVISION.

 

COMMON
STOCK PURCHASE WARRANT

 

ADHERA
THERAPEUTICS, INC.

 

	Warrant Shares:
  476,190	Initial Issue Date:
  October 7, 2021
	Aggregate Exercise Amount: $45,238.05	 

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, BLUE LAKE PARTNERS, LLC, a Delaware
limited liability company, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations
on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Issue Date”)
and on or prior to the close of business on the three (3) year anniversary of the Initial Issue Date (as subject to adjustment hereunder,
the “Termination Date”), to subscribe for and purchase from ADHERA THERAPEUTICS, INC., a Delaware corporation (the
“Company”), up to 476,190 shares (as subject to adjustment herein, the “Warrant Shares”) of common
stock of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall
be equal to the Exercise Price, as defined in Section 1.2.

 

ARTICLE
1 EXERCISE RIGHTS

 

The
Holder will have the right to exercise this Warrant to purchase shares of Common Stock as set forth below.

 

1.1
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time,
by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered
Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile or emailed copy of the Notice
of Exercise form annexed hereto. Within three (3) business days following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or check drawn on a United
States bank unless the cashless exercise procedure specified in Section 1.3 below is specified in the applicable Notice of Exercise.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise form within two (2) business days of receipt
of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.

 

1.2
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.095 per share, subject to adjustment
hereunder (the “Exercise Price”). The aggregate exercise price is $45,238.05.

 

1.3
Cashless Exercise. In the event that shares covered by this Warrant are not registered for resale by the Holder at prevailing
market prices pursuant to an effective registration statement which contains a prospectus that complies with Section 5(b) and Section
10 of the Securities Act of 1933 at the time of exercise, then, in addition to a cash exercise, this Warrant may also be exercised, in
whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

 

    	1

    	 

    

 

 

(A)
= the closing price of the Common Stock immediately preceding the date on which Holder elects to exercise this Warrant by means of a
“cashless exercise,” as set forth in the applicable Notice of Exercise;

 

(B)
= the Exercise Price of this Warrant, as adjusted hereunder; and

 

(X)
= the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

 

1.4
Delivery of Warrant Shares. Warrant Shares purchased hereunder will be delivered to Holder within three (3) business days of Notice
of Exercise by “DWAC/FAST” electronic transfer (such date, the “Warrant Share Delivery Date”) or by delivery
of physical certificate. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date of delivery of the Notice of
Exercise. Holder may assess penalties or liquidated damages (both referred to herein as “penalties”) as follows. For each
exercise, in the event that shares are not delivered by the third business day (inclusive of the day of exercise if received before 4:00
pm EST), the Company shall pay the Holder in cash a penalty of $1,000 per day for each day after the third business day until share delivery
is made. The Company will not be subject to any penalties once its transfer agent correctly processes the shares to the DWAC system.
The Company will make its best efforts to deliver the Warrant Shares to the Holder the same day or next day after receipt of the Notice
of Exercise.

 

1.5
Delivery of Warrant. The Holder shall not be required to physically surrender this Warrant to the Company. If the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, this Warrant shall automatically be cancelled
without the need to surrender the Warrant to the Company for cancellation. If this Warrant shall have been exercised in part, the Company
shall, at the request of Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant and, for purposes of Rule 144 or other applicable exemption, shall tack back
to the original date of this Warrant.

 

1.6
Intentionally Omitted.

 

1.7
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In addition to any other rights available to
the Holder, if the Company fails to abide by the terms of this Warrant and fails to cause its transfer agent to transmit to the Holder
the Warrant Shares on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including
brokerage commissions and other fees, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
(x) reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case
such exercise shall be deemed rescinded), (y) deliver to the Holder the number of shares of Common Stock that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder, or (z) pay in cash to the Holder the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed. The Holder shall provide the
Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount of such loss.

 

    	2

    	 

    

 

1.8
Make-Whole for Market Loss after Exercise. At the Holder’s election, if the Company fails to abide by the terms of this
Warrant and fails to deliver to the Holder the Warrant Shares by DWAC/FAST electronic transfer (such as by delivering a physical certificate)
and if the Holder incurs a Market Price Loss, then at any time subsequent to incurring the loss the Holder may provide the Company written
notice indicating the amounts payable to the Holder in respect of the Market Price Loss and the Company must make the Holder whole as
follows:

 

Market
Price Loss = [(High trade price on the day of exercise) x (Number of Warrant Shares)] – [(Sales price realized by Holder) x (Number
of Warrant Shares)]

 

The
Company must pay the Market Price Loss by cash payment, and any such cash payment must be made by the third business day from the time
of the Holder’s written notice to the Company.

 

1.9
Make-Whole for Failure to Deliver Loss. At the Holder’s election, if the Company fails to abide by the terms of this Warrant
and fails for any reason to deliver to the Holder the Warrant Shares by the Warrant Share Delivery Date and if the Holder incurs a Failure
to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable to the Holder in respect
of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

 

Failure
to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of Warrant Shares)]

 

The
Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day from the
time of the Holder’s written notice to the Company.

 

1.10
Choice of Remedies. Nothing herein, including, but not limited to, Holder’s electing to pursue its rights under Sections
1.8 or 1.9 of this Warrant, shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

1.11
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Company for any issue or transfer
tax or other incidental expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Holder,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder. The Holder
shall pay all transfer agent fees required for same-day processing of any Notice of Exercise.

 

1.12
Holder’s Exercise Limitations. Unless otherwise agreed in writing by both the Company and the Holder, at no time will the
Holder exercise any amount of this Warrant to purchase Common Stock that would result in the Holder owning more than 4.99% of the Common
Stock outstanding of the Company (the “Beneficial Ownership Limitation”). Upon the written request of Holder, the
Company shall within two (2) business days confirm in writing to the Holder the number of shares of Common Stock then outstanding.

 

ARTICLE
2 ADJUSTMENTS

 

2.1
Stock Dividends and Splits. If the Company, at any other time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 2.1 shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.

 

    	3

    	 

    

 

2.2
Pro Rata Distributions. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common
Stock (and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock, then in each such case the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution
by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator
shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or
evidence of indebtedness or rights or warrants so distributed applicable to one outstanding share of the Common Stock as determined by
the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the
portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned
above.

 

2.3
Intentionally Omitted.

 

2.3
Notice to Holder. Whenever the Exercise Price is adjusted pursuant to any provision of this Article 2, the Company and the Holder
shall promptly notify each other (by written notice) setting forth the proposed Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ARTICLE
3 COMPANY COVENANTS

 

3.1
Reservation of Shares. As of the issuance date of this Warrant and for the remaining period during which the Warrant is exercisable,
the Company will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of Warrant
Shares upon the full exercise of this Warrant. The Company represents that upon issuance, such Warrant Shares will be duly and validly
issued, fully paid and non-assessable. The Company agrees that its issuance of this Warrant constitutes full authority to its officers,
agents and transfer agents who are charged with the duty of executing and issuing shares to execute and issue the necessary Warrant Shares
upon the exercise of this Warrant. No further approval or authority of the stockholders of the Board of Directors of the Company is required
for the issuance of the Warrant Shares

 

3.2
No Adverse Actions. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including,
without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

ARTICLE
4 MISCELLANEOUS

 

4.1
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

    	4

    	 

    

 

4.2
Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including,
without limitation, any registration rights) are transferable, in whole or in part, by a written assignment of this Warrant duly executed
by the Holder or its agent or attorney. If necessary to obtain a new warrant for any assignee, the Company, upon surrender of this Warrant,
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of
this Warrant not so assigned, and such new Warrants, for purposes of Rule 144 or other applicable exemption, shall tack back to the original
date of this Warrant. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.

 

4.3
Assignability. The Company may not assign this Warrant. This Warrant will be binding upon the Company and its successors, and
will inure to the benefit of the Holder and its successors and assigns, and may be assigned by the Holder to anyone of its choosing without
the Company’s approval.

 

4.4
Notices. Any notice required or permitted hereunder must be in writing and either personally served, sent by facsimile or email
transmission, or sent by overnight courier. Notices will be deemed effectively delivered at the time of transmission if by facsimile
or email, and if by overnight courier the business day after such notice is deposited with the courier service for delivery.

 

4.5
Governing Law. This Warrant will be governed by, and construed and enforced in accordance with, the laws of the State of Delaware,
without regard to the conflict of laws principles thereof. Any action brought by either party against the other concerning the transactions
contemplated by this Warrant shall be brought only in the state courts of Palm Beach County, Florida or in the federal courts located
in Palm Beach County, Florida. Both parties and the individuals signing this Agreement agree to submit to the jurisdiction of such courts.

 

4.6
Delivery of Process by Holder to the Company. In the event of any action or proceeding by Holder against the Company, and only
by Holder against the Company, service of copies of summons and/or complaint and/or any other process which may be served in any such
action or proceeding may be made by Holder via U.S. Mail, overnight delivery service such as FedEx or UPS, or process server to the Company
at its last known address or to its last known attorney set forth in its most recent SEC filing.

 

4.7
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1.1. So long as this Warrant is unexercised, this
Warrant carries no voting rights and does not convey to the Holder any “control” over the Company, as such term may be interpreted
by the SEC under the Securities Act or the Exchange Act, regardless of whether the price of the Company’s Common Stock exceeds
the Exercise Price.

 

4.8
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

4.9
Attorney Fees. In the event any attorney is employed by either party to this Warrant with regard to any legal or equitable action,
arbitration or other proceeding brought by such party for the enforcement of this Warrant or because of an alleged dispute, breach, default
or misrepresentation in connection with any of the provisions of this Warrant, the prevailing party in such proceeding will be entitled
to recover from the other party reasonable attorneys’ fees and other costs and expenses incurred, in addition to any other relief
to which the prevailing party may be entitled.

 

4.10
Opinion of Counsel. In the event that an opinion of counsel is needed for any matter related to this Warrant, Holder has the right
to have any such opinion provided by its counsel.

 

4.11
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.

 

4.12
Amendment Provision. The term “Warrant” and all references thereto, as used throughout this instrument, means this
instrument as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

4.13
No Shorting. Holder agrees that so long as this Warrant remains unexercised in whole or in part, Holder will not enter into or
effect any “short sale” of the common stock or hedging transaction which establishes a net short position with respect to
the common stock of the Company. The Company acknowledges and agrees that as of the date of delivery to the Company of a fully and accurately
completed Notice of Exercise, Holder immediately owns the common shares described in the Notice of Exercise and any sale of those shares
issuable under such Notice of Exercise would not be considered short sales.

 

*
* *

 

    	5

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	ADHERA THERAPEUTICS, INC.
	 	 	 
	 	By:
     	
	 	Name:	Andrew
    Kucharchuk
	 	Title:	Chief
    Executive Officer

 

    	6

    	 

    

 

NOTICE
OF EXERCISE

 

To:
ADHERA THERAPEUTICS, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[
] in lawful money of the United States; or

 

[
] the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 1.3, to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
Section 1.3.

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

_______________________________

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

	[SIGNATURE OF
HOLDER]	 
	 	            	 
	Name:		
	Date:		
	 	 	 

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]